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Abstract
Previous studies show inconsistent associations between α-linolenic acid (ALA) and risk of CHD. We aimed to examine an aggregate
association between ALA intake and risk of CHD, and assess for any dose–response relationship. We searched the PubMed, EMBASE and Web
of Science databases for prospective cohort studies examining associations between ALA intake and CHD, including composite CHD and fatal
CHD. Data were pooled using random-effects meta-analysis models, comparing the highest category of ALA intake with the lowest across
studies. Subgroup analysis was conducted based on study design, geographic region, age and sex. For dose–response analyses, we used two-
stage random-effects dose–response models. In all, fourteen studies of thirteen cohorts were identified and included in the meta-analysis. The
pooled results showed that higher ALA intake was associated with modest reduced risk of composite CHD (risk ratios (RR)= 0·91; 95% CI
0·85, 0·97) and fatal CHD (RR= 0·85; 95% CI 0·75, 0·96). The analysis showed a J-shaped relationship between ALA intake and relative risk of
composite CHD (χ2= 21·95, P< 0·001). Compared with people without ALA intake, only people with ALA intake <1·4 g/d showed reduced
risk of composite CHD. ALA intake was linearly associated with fatal CHD – every 1 g/d increase in ALA intake was associated with a 12%
decrease in fatal CHD risk (95% CI −0·21, −0·04). Though a higher dietary ALA intake was associated with reduced risk of composite and fatal
CHD, the excess composite CHD risk at higher ALA intakes warrants further investigation, especially through randomised controlled trials.
Key words: α-Linolenic acid: CHD: Meta-analyses: Dose–response relationships
According to the WHO, IHD or CHD accounted for 7·4 million
deaths in 2012, the leading cause of death worldwide(1,2). There is
growing evidence showing that long-chain n-3 PUFA, particularly
EPA (C20 : 5n-3) and DHA (C22 : 6n-3), are beneficial for preven-
tion of CVD(3). The American Heart Association recommends two
servings of fatty fish per week or 500mg EPA and DHA per day be
taken for those without CHD, and 1g/d of EPA/DHA for those with
CHD(4). The main source of EPA and DHA is fish(5). However, the
increasing demand on fish consumption may cause problems of
sustainability in provision of fish, and pollution – specifically, the
accumulation of toxic materials – may neutralise the health benefits
of fish, or even have adverse effects(6). Also, fish is not applicable
for most vegetarians. Therefore, alternative sources of EPA and
DHA are needed to maintain the level of intake.
Abbreviations: ALA, α-linolenic acid; RR, risk ratio.
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α-Linolenic acids (ALA), an n-3 fatty acid mainly derived from
soyabean, flaxseed and walnuts has been proposed as a
potential substitution for fish. ALA is converted to long-chain
n-3 fatty acids in the body, including EPA and DHA, though the
efficiency is low(7). A number of studies have been conducted
to examine associations between ALA intake and CHD risk(8),
though the results were inconsistent.
A previous meta-analysis of Pan et al.(9) indicates that a higher
level of ALA intake is associated with reduced risk of fatal CHD,
whereas not associated with risk of non-fatal CHD or composite
CHD. It also indicates that each additional 1 g/d ALA intake is
associated with a 10% reduction in risk of fatal CHD. Recently,
several new studies have examined the associations between ALA
intake and risk of CHD(10–14), so an updated aggregate association
may be informative. Moreover, it will be beneficial to explore the
optimal dosing of ALA intake for prevention of CHD – specifi-
cally, what threshold of intake is needed for benefit and whether
higher doses confer additional benefit. We systematically
reviewed the literature and conducted a meta-analysis to inves-
tigate the potential dose–response relationship between ALA
intake and CHD risk. We hypothesised that higher intake of ALA
is linearly associated with lower risk of composite and fatal CHD.
Methods
Search strategy and eligibility criteria
We systematically searched the PubMed, Embase and Web of
Science databases for epidemiological studies published in
peer-reviewed journals over a 50-year period (from January
1966 to August 2017) that investigated the associations between
dietary ALA intake and CHD. Search terms included ‘alpha-
linolenic acid’, ‘cardiovascular disease’, ‘coronary heart
disease’, ‘coronary artery disease’, ‘ischemic heart disease’
and ‘myocardial infarction’ (see the online Supplementary
Appendix). We also searched for studies listed or cited in
review papers, in case there were potential studies not captured
by the database search strategy. The search was limited to
articles written in English. We contacted authors of included
articles if important information was missing.
We included original full-text studies that were: (1) cohort
studies, (2) included adult participants free from CHD history with
assessments of dietary intake of ALA, (3) assessed primary
outcomes including fatal and/or non-fatal CHD and (4) had a
comparison between the highest and the lowest level of dietary
ALA intake. We excluded studies that: (1) included only assessed
ALA level in plasma or serum as biomarkers, and (2) included
composite outcomes that combined different cardiovascular
events and CHD could not be distinguished. If there were several
studies based on the same cohort, we retained the studies with the
most directly relevant results for particular outcomes.
Study selection was conducted in three steps. First, the titles
of studies identified in our literature search were independently
reviewed by three reviewers (J. W., R. H., Y. X.). Second, the
abstracts of studies that remained after the initial screening
were reviewed by three reviewers and disagreements were
reconciled. Third, data from studies that met inclusion criteria
were extracted, including sample size, study design, age, sex,
methods of assessing dietary intake of ALA, amount of ALA
intake, outcome of studies and covariates included in the
analysis.
Definitions
The information regarding dietary ALA intake was obtained
from validated tools, such as FFQ, 24-h dietary recalls, dietary
history and food records. The outcomes of our proposed meta-
analysis were CHD events defined as one of the following
terms: coronary heart disease, coronary artery disease, ischemic
heart disease, or myocardial infarction. Composite CHD was
defined as total incident cases of CHD events reported in the
studies, including fatal or non-fatal CHD. The definition of fatal
CHD included CHD death or CHD mortality mentioned in the
articles. If a study reported only fatal CHD or non-fatal CHD,
then it would be also counted into composite CHD. All incident
cases were ascertained by physician diagnosis, medical records
or death certificate.
Quality assessment
Quality assessment was conducted using the Newcastle–Ottawa
Scale(15). The Newcastle–Ottawa Scale evaluates quality of
cohort studies in three domains:
(1) selection of exposed and non-exposed cohorts (representa-
tiveness of the exposed cohort, selection of the non-exposed
cohort, ascertainment of exposure, and demonstration of
absence of outcome at the beginning of studies);
(2) comparability of exposed and non-exposed cohorts
(analysis appropriately adjusted for potential confounding
factors, including the most important and additional factors,
such as medications, history of other chronic diseases and
lifestyle factors); and
(3) outcome ascertainment (adequacy of outcome assessment,
length of follow-up and adequacy of follow-up).
A study would be awarded a maximum of 1 point for each
variable within each assessment domain (selection, compar-
ability, and outcome) for a possible maximum total score of 9.
The quality assessment was conducted independently by two
reviewers (R. H. and A. K.), and the results were reconciled
until a consensus was reached.
Statistical analysis
We obtained fully adjusted risk ratios (RR) and 95% CI from
each study. We pooled data across studies using random-effects
meta-analysis models, and weighted these by the inverse of the
estimated variance, comparing the highest category of ALA
intake with the lowest as indicated in each study. We con-
sidered the pooled RR to be statistically significant if 95% CI did
not contain 1. We generated forest plots to illustrate individual
and pooled risk estimates, and funnel plots to examine potential
publication bias. We calculated the I2 statistic to quantify the
proportion of between-study heterogeneity attributable to
variability in the association rather than sampling variation. We
also conducted subgroup analyses to examine for heterogeneity
of associations by regions where studies were conducted (North
America, Europe, Asia), mean age of study participants (≥60
years or not), and percentage of female subjects (≥50% or not).
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To examine impacts of the amount of ALA intake and risk of
CHD, we conducted a dose–response meta-analysis for each
outcome. For each study, we assigned the median or mean
grams of ALA for each exposure level to the corresponding RR.
To explore potential linear and non-linear relationships
between ALA intake and CHD risk, we performed random-
effects dose–response meta-analyses. We estimated the pre-
dicted relative risk by comparing specific levels of ALA intake
with no ALA intake based on the linear model or spline trans-
formation, as appropriate. The linear or non-linear relationship
between dietary ALA intake and CHD risk was considered
significant if the p value of the chi-square statistic was smaller
than 0·05.
All analyses were conducted using Stata 14 (StataCorp).
Results
Study characteristics
The database search started with a total of 1853 citations
(Fig. 1). We identified an additional twelve studies from the
bibliographies of relevant reports and reviews. After eliminating
duplicates, 1422 remained. Of these, we excluded 1368 studies
due to irrelevant topics, non-prospective designs, or assess-
ments of exposures and outcomes not meeting the inclusion
criteria. We retrieved full-texts of the fifty-four remaining articles
to be examined in more detail. Of these, fourteen prospective
studies eventually met all inclusion criteria and were included in
the systematic review and meta-analysis.
The online Supplementary Table S1 showed characteristics of
included studies. The pooled analysis included data from
345 202 individuals, with a mean length of follow-up between
4 and 22 years. The mean (median) ages of participants ranged
from 41·5 to 73·0 years. Included studies were conducted in the
USA, the Netherlands, Finland, Denmark, Spain and Singapore.
Two studies stratified the analysis into male and female
participants separately(14,16). Two studies were based on the
same cohort (one is used for meta-analysis, and one for
dose–response analysis). Nine studies examined associations
between dietary ALA intake and risk of composite
CHD(10,11,14,16–22). Eight studies examined fatal CHD as
outcomes(11–13,17–19,23,24).
1853 articles from three databases:
– 633 from PubMed
– 979 from Web of Science
– 241 from Embase 12 articles from other sources
443 duplicates excluded
1422 abstracts reviewed
1368 excluded:
– Not prospective
– Case report or review article
– Not relevant
– Did not measure ALA alone out of
   all n-3 fatty acids
54 full-text articles reviewed
40 excluded:
– Combining cohorts for mixed
   outcome
– Not distinguish CHD among overall
   cardiovascular events
14 studies included in
qualitative synthesis
14 studies included in meta-
analysis
Fig. 1. Flow chart showing selection of study reports for the meta-analysis. ALA, α-linolenic acid.
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Pooled analyses
The meta-analysis of fourteen groups of analysis across twelve
studies showed that higher intake of ALA was moderately asso-
ciated with reduced risk of composite CHD (Fig. 2(a), pooled
(RR=0·91; 95% CI 0·85, 0·97). The analysis of nine studies indicated
that a higher dietary ALA intake was associated with a lower risk
of fatal CHD (Fig. 2(b), pooled RR=0·85; 95% CI 0·75, 0·96).
Heterogeneity was not detected in the associations with ALA intake
with risk of composite CHD (I2=7·9%, P=0·36), or fatal CHD
Study
HPFS
ATBC
Zutphen Elderly Study
MORGEN
Glostrup Population Studies-men
Glostrup Population Studies-women
NHS
CHS
MESA
SCHS
PREDIMED
MRFIT
Danish-men
Danish-women
Women’s Health Study
Overall (I 2= 7.9 %, P = 0.364)
ES 95 % Cl Weight (%)
0.99 0.78, 1.25
0.75 0.36, 1.58
0.68 0.40, 1.15
0.81 0.72, 0.91
1.03 0.83, 1.28
0.91 0.85, 0.97 100.00
0.5 1.5 2.01.0
0.80 0.63, 1.02
0.96 0.80, 1.15
0.87 0.70, 1.08
1.68 0.86, 3.29
1.01 0.66, 1.54
0.83 0.56, 1.24
1.04 0.58, 1.86
0.61 0.29, 1.28
0.93 0.67, 1.30
0.99 0.86, 1.14
6.73
12.08
8.46
0.97
2.39
2.71
1.28
0.79
3.84
17.61
8.48
24.99
1.58
0.80
7.27
Study
HPFS
ATBC
Zutphen Elderly Study
NHS
CHS
SCHS
PREDIMED
MRFIT
Danish
Overall (I 2= 15.8 %, P = 0.301)
ES 95 % Cl Weight (%)
1.59 0.62, 4.08
0.55 0.32, 0.94
1.03 0.72, 1.47
0.81 0.72, 0.91
0.75 0.36, 1.58
0.68 0.40, 1.15
0.71 0.47, 1.08
1.03 0.66, 1.60 7.01
0.99 0.76, 1.28 16.79
0.85 0.75, 0.96 100.00
7.73
5.09
2.64
43.98
10.27
4.83
1.66
0.5 1.51.0 2.0
(a)
(b)
Fig. 2. Pooled association between dietary α-linolenic acid (ALA) intake and risk of (a) composite CHD and (b) fatal CHD. Weights are from random-effects analysis.
ES, effect size; HPFS, Health Professionals Follow-Up Study; ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention; NHS, Nurses' Health Study; MORGEN,
Monitoring Project on Risk Factors and Chronic Diseases in the Netherlands; MESA, Multi-Ethnic Study of Atherosclerosis; CHS, Cardiovascular Health Study; SCHS,
Singapore Chinese Health Study; MRFIT, Multiple Risk Factor Intervention Trial; PREDIMED, Prevención con Dieta Mediterránea.
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(I2=15·8%, P=0·30). There was no detected publication bias
across studies, as the funnel plots showed good symmetry (online
Supplementary Fig. S1 and S2).
Results of subgroup analyses showed that a higher ALA
intake was associated with risk reductions of composite CHD in
studies conducted in North America and Asia, studies with a
lower percentage of female participants (<50%) and studies
with lower mean age (<60 years). For fatal CHD, subgroup
analyses showed risk reductions with ALA intake in studies
conducted in Asia, studies with more female (≥50%) and
younger (<60 years) participants (Table 1).
The two-stage random-effects dose–response analysis did not
show a linear relationship between dietary ALA intake and
relative risk of composite CHD (χ2= 1·13, P= 0·29), but rather a
J-shaped curve between ALA intake and relative risk of com-
posite CHD (χ2= 21·95, P< 0·001). ALA intake<1·4 g/d showed
reduced risk of composite CHD, compared with people without
ALA intake. A quantity of 1 g of ALA intake per day was asso-
ciated with the lowest risk of CHD (Fig. 3(a)). There was a linear
relationship between ALA intake and risk of fatal CHD. ALA
intake, 1 g/d, was associated with 12% decrease in risk of fatal
CHD (β= − 0·12; 95% CI −0·21, −0·04) (Fig. 3(b)).
Quality assessment
The quality of the fourteen studies included in the meta
analysis, as scored with the Newcastle–Ottawa scale, is presented
in the online Supplementary Table S2. The mean total quality
score was 7·4 out of a maximum score of 9 (range 7–9) indicating
that, overall, the methodological quality among cohort studies
was moderately good.
Discussion
The present systematic review and meta-analysis showed
significant associations between a higher ALA intake with
reduced risk of composite CHD and fatal CHD. Our dose–
response analysis showed that compared with people without
intake of ALA, only a certain range of ALA intake (<1·4 g/d)
was associated with reduced risk of CHD. In contrast, a higher
intake of ALA was associated with reduced risk of fatal CHD. To
our knowledge, this is the largest meta-analysis of dietary ALA
intake and CHD risk based on prospective studies. However,
given the present publication bias and heterogeneity among
studies, the results should be interpreted with caution.
Table 1. Subgroup meta-analysis of the pooled analysis between dietary α-linolenic acid (ALA) intake and risk of CHD
(Pooled risk ratios (RR) and 95% confidence intervals)
Composite CHD (n 12) Fatal CHD (n 9)
Number of studies Pooled RR 95% CI I2 (%)* Number of studies Pooled RR 95% CI I2 (%)
Regions
North America 6 0·88 0·80, 0·98 0 4 0·83 0·62, 1·12 40·8
Europe 6 0·99 0·90, 1·08 0 4 0·91 0·72, 1·15 11·0
Asia 1 0·81 0·72, 0·90 NA 1 0·81 0·72, 0·90 NA
Mean age
≥60 years 4 0·94 0·66, 1·34 33·8 3 1·02 0·76, 1·38 0·0
<60 years 9 0·90 0·85, 0·96 4·1 6 0·82 0·72, 0·94 18·7
Female†
≥50% 9 0·88 0·82, 0·95 0·0 4 0·81 0·68, 0·97 20·8
<50% 6 0·93 0·82, 1·05 28·1 5 0·90 0·74, 1·11 13·2
RR, risk ratio; NA, not applicable.
* P> 0·05 for all I 2.
† For composite CHD, two studies were analysed by sex, so they were included in both categories.
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Fig. 3. Dose–response relationship between α-linolenic acid (ALA) intake and
relative risk of (a) composite CHD and (b) fatal CHD. Weights are from random-
effects analysis. , Lower limit of 95% CI; , upper limit of 95% CI;
, risk ratio.
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Our results were similar with previous studies to some extent.
Pan et al.(9) showed a significant inverse association and a
linear dose–response relationship between ALA intake and risk
of fatal CHD, though it did not show an overall CHD outcome,
but a composite of all cardiovascular events, including CHD,
stroke and other CVD events with an association of similar
magnitude. Vedtofte et al.(25) previously found that 1 g/d of ALA
consumed was associated with a 15% lower risk of CHD events
and a 23% lower risk of CHD deaths in males. Although it did
not reach statistical significance, a potential non-linear rela-
tionship was not tested. Our dose–response analysis indicated a
non-linear relationship between ALA intake and risk of com-
posite CHD, which suggested a beneficial level of dietary ALA
intake for prevention of CHD. The National Academy of Med-
icine recommended that men should consume 1·6 g of ALA
per day and women should consume 1·1 g/d(26). This is similar
to our present result of optimal level of ALA (1 g/d) in the dose–
response meta-analysis.
Although ALA shows promising benefits in CHD prevention,
the effect seems to be smaller than expected, particularly our
dose–response analysis showed a non-linear relationship. This
may be explained by residual or unknown confounding effects,
such as intake of other fatty acids or dietary components related
to risk of CHD. Furthermore, as Oomen et al.(19) point out, that
intake of ALA may be associated with intake of trans-fatty acids,
which is associated with an increased risk of CHD(19). ALA and
trans-fatty acids are also found correlated in biomarkers(27).
According to our present results, it is likely that under a certain
amount of ALA intake, ALA has an effect over trans-fatty acids,
whereas trans-fatty acids may play a more important role in
association with CHD. However, this does not affect an
expected trend of risk in fatal CHD.
The mechanisms of association between dietary ALA intake
and CHD are not fully understood yet. The conversion from
ALA to EPA and DHA may partially account for the association,
whereas previous studies have found that only very limited
amounts of ALA were actually converted(28), so the efficiency is
not high. Currently, there is no solid evidence showing a direct
causal relationship between dietary ALA intake and CHD risk,
whereas previous epidemiological studies showed some clues,
for example, Lemaitre et al.(29) found an association between
ALA in erythrocytes and risks of sudden cardiac death, which is
independent of erythrocyte levels of EPA and DHA, linoleic
acid and trans-fatty acids. There are more plausible mechan-
isms to account for the association between ALA intake and
CHD, such as reduced inflammation, which is found to be
associated with higher intake of nuts(30). Potential biological
research is needed to further elucidate the mechanisms
involved.
Our findings have significant relevance for public health and
medicine. A number of studies also examined the association of
biomarkers of ALA and CHD risk, whereas studies may have a
better significance in guidance of human diet with dietary ALA
intake as an exposure Diet has been recognised as an essential
aspect in preventing CHD. In commonly applied dietary pat-
terns for prevention of CVD, such as the Mediterranean dietary
pattern(31) and Dietary Approaches to Stop Hypertension(32),
both emphasize intake of fish, which is the main source of EPA
and DHA. As an alternative source of EPA and DHA, ALA
should be considered as an important element in CHD pre-
vention, as the potential for supplying ALA is great(5). It is
expected that a guideline for specific groups of foods and
amount be made to the public for self-administered prevention
of CHD. Furthermore, ALA could potentially lead to pharma-
cological applications. Randomised controlled trials on CHD
patients have shown that ALA intake may reduce risk of CHD
events, including recurrence of CHD and CHD death(33,34).
Future randomised controlled trials are needed to examine the
effects of ALA on reducing primary CHD risk.
Our present study had some noteworthy limitations. First, all
the included studies did not report uniform levels of dietary ALA
intake and did not report the same outcomes, although the
results were consistent in general. Second, our present meta-
analysis of prospective cohort studies only included two ran-
domised controlled trials. More randomised controlled trials of
the effect of ALA intake on reduction of CHD are needed to
remove all unmeasured confounding that may still plague
prospective observational studies.
In conclusion, existing prospective studies suggest that
higher ALA intake is associated with reduced risk of composite
CHD and fatal CHD. Though a higher dietary ALA intake was
associated with reduced risk of fatal CHD, the excess composite
CHD risk at higher ALA intakes warrants further investigation,
especially through randomised controlled trials.
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